by Ned Mumtaz | Jun 11, 2026 | en
tradurre in italiano Why the Italian Sunshine Act Is More Operationally Complex Than US Open Payments Table of content Italy’s Life Sciences Market Demands Attention Broader Covered Entities, Including Sectors the US Does Not Touch A Broader Pool of Covered...
by May Khan | Jun 4, 2026 | en
tradurre in italiano Transfers of Value: The One Concept Italian Life Sciences Companies Cannot Afford to Get Wrong Table of content The Real Question Is Not Only How to Report — It Is Also What to Report Why Companies Underestimate This Step What Good TOV Preparation...
by Umer Tanweer | May 28, 2026 | en
tradurre in italiano From Chaos to Compliance: How to Coordinate Multiple Departments for Italian Sunshine Act Reporting Table of content Mapping Who Owns What Designing the Data Collection Workflow Training: Two Levels, Two Different Messages External Stakeholders:...
by Ned Mumtaz | May 14, 2026 | en
tradurre in italiano HCP Engagement in Italy 2026: Italian Sunshine Act, Sanità Trasparente & Telematic Register Table of content Introduction How the Italian Sunshine Act Is Transforming HCP Engagement Why 2026 Represents a Turning Point for HCP Engagement in...
by Edoardo Lazzarini | May 6, 2026 | en
tradurre in italiano The compliance risk that many Italian life sciences companies are still underestimating before Sanità Trasparente becomes operational Table of content Sanità Trasparente Reporting: operational challenges in transparency compliance for the human...
by Ned Mumtaz | Apr 29, 2026 | en
tradurre in italiano What the US Sunshine Act Taught Us About HCP Interactions— And What Italian Companies Should Learn Table of content The Italian HCP’s Starting Point Why Manufacturers Should Lead the Conversation What Good Healthcare Interactions Look Like...
